GALIMBERTI, MIRIAM
GALIMBERTI, MIRIAM
Universita' degli Studi di MILANO
NAT2 Acetylation Status Predicts Hepatotoxicity During Antituberculosis Therapy: Cumulative Risk Analysis of a Multiethnic Cohort
2025 M. Schiuma, S. Dinegro, V. Battini, A. Torre, A. Covizzi, A. Civati, M. Galimberti, I. Mariani, G. Mosini, C. Carnovale, A. Riva, A. Gori, S. Antinori, E. Clementi, S. Radice, S. Cheli
NAT2 Slow Acetylator Phenotype as a Significant Risk Factor for Hepatotoxicity Caused by Antituberculosis Drugs: Results From a Multiethnic Nested Case-Control Study
2024 S. Cheli, A. Torre, M. Schiuma, C. Montrasio, A. Civati, M. Galimberti, V. Battini, I. Mariani, G. Mosini, C. Carnovale, S. Radice, E. Clementi, A. Gori, S. Antinori
Bloodstream Infections in Intensive Care Unit during Four Consecutive SARS-CoV-2 Pandemic Waves
2023 G. Pozza, G. Casalini, C.L. Ciubotariu, A. Giacomelli, M. Galimberti, M. Zacheo, A. Rabbione, M. Pieruzzi, L. Oreni, L. Galimberti, R. Colombo, G. Rizzardini, C. Pagani, S.G. Rimoldi, C. Bonazzetti, A. Lisa Ridolfo, S. Antinori
Challenges in Diagnosing COVID-19-Associated Pulmonary Aspergillosis in Critically Ill Patients: The Relationship between Case Definitions and Autoptic Data
2022 G. Casalini, A. Giacomelli, L. Galimberti, R. Colombo, E. Ballone, G. Pozza, M. Zacheo, M. Galimberti, L. Oreni, L. Carsana, M. Longo, M.R. Gismondo, C. Tonello, M. Nebuloni, S. Antinori